Actively Recruiting
Long-Term Observational Study of Guselkumab Use in Adults with Moderate to Severe Inflammatory Bowel Disease
Led by Janssen Research & Development, LLC · Updated on 2026-11-03
400
Participants Needed
1
Research Sites
14 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying how long adults with moderate to severe Crohns disease or ulcerative colitis continue their treatment with the medicine guselkumab in real-world clinical settings. These conditions are inflammatory diseases affecting the colon and small intestine. The goal is to understand treatment persistence, or how long patients stick with their prescribed therapy without stopping. Participants with confirmed moderate to severe Crohns disease or ulcerative colitis will be treated with guselkumab according to local medical guidelines and clinical practice. This study does not provide the drug instead, it collects data from routine clinical care. The study will observe and record treatment use and patient responses over time without altering their prescribed treatment plans. During the study, researchers will collect data on participants health status, treatment persistence, early treatment responses, clinical remission, quality of life, and safety measures up to 96 weeks. Assessments include patient-reported outcomes, clinical scores, laboratory tests, imaging, and treatment satisfaction surveys. Participants medical histories and disease characteristics will also be recorded. The study aims to monitor participants progress and treatment outcomes while they receive usual care, with a total observation period extending up to nearly four years.
CONDITIONS
Brief Title
A Study of Long Term Persistency of Guselkumab in Adult Participants With Inflammatory Bowel Disease
Research Team
S
Study Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here